CDMO Rentschler Biopharma began construction of a new buffer media station at its company headquarters in Laupheim, Germany. The facility aims to further increase production efficiency and modernize the site, ensuring that the evolving needs of clients and patients are anticipated and fully met, both now and in the future, according to Benedikt von Braunmühl, CEO of Rentschler Biopharma.
“This investment underscores our commitment to the long-term development of our Laupheim site, a key part of Germany’s biotechnology landscape. This expansion will strengthen our competitive position in one of the world’s fastest-growing industries,” he said. “Government support for a German national pharmaceutical strategy is an important signal for the industry as a whole. While our focus remains on strengthening global partnerships, this investment in our German site plays a crucial role in ensuring supply chain reliability and advancing our long-term growth strategy.”
The new facility will include three media tanks and six buffer tanks, set up to provide sufficient space and capacity for the production of buffer solutions and media. Buffer and media preparation will be carried out in separate areas to ensure the highest standards of hygiene and safety, noted Christiane Bardroff, COO at Rentschler, who pointed out that the facility will be connected to the in-house logistics system and the piping system for upstream and downstream processes.
Detailed planning for the new building has already begun, and construction is scheduled to start in spring 2025. Completion and operational launch are planned by the end of 2027.
